ILUSTRASI. Moderna Inc on Wednesday retained its full-year sales outlook for Covid-19 shot at US$ 21 billion due to a decrease in orders from low- and middle-income countries. REUTERS/Michele Tantussi
Sumber: Reuters | Editor: Anastasia Lilin Yuliantina
KONTAN.CO.ID - Moderna Inc on Wednesday retained its full-year sales outlook for Covid-19 shot at US$ 21 billion due to a decrease in orders from low- and middle-income countries through the COVAX international vaccine-sharing program.
The company kept its forecast unchanged despite announcing a new US$ 1,74 billion deal with the US government for 66 million Covid-19 booster doses last week.
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan atau membeli artikel ini.
Sudah berlangganan? Masuk
Berlangganan Hanya dengan 20rb/bulan Anda bisa mendapatkan berita serta analisis ekonomi, bisnis, dan investasi pilihan
Business Insight, Epaper Harian + Tabloid, Arsip Epaper 30 Hari
Gratis uji coba 7 hari pertama. Anda dapat menggunakan akun Google sebagai metode pembayaran.
